PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT
MEMORANDUM
TO: James Prentice, Sandra Tung, Tiffany Rosenthal, Andrew Fitzpatrick — Calderwood & Harkness LLP Deal Team
FROM: Leonard Cross, Specialist Partner, Tax — Calderwood & Harkness LLP
DATE: May 5, 2023
RE: Tax Structuring Analysis — Asset Purchase of OncuPath™ Business by Meridian Precision Diagnostics, Inc.
MATTER NO.: 1013-00006&A-4471
CLIENT: Genome Dx Therapeutics Inc.
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to analyze the federal and state income tax implications of the proposed $140,000,000 asset purchase of the OncuPath™ companion diagnostics assay line (the "OncuPath Business") by Meridian Precision Diagnostics, Inc. ("Buyer" or "Meridian") from Genome Dx Therapeutics Inc. ("Seller" or "GDT"). This memorandum is intended to provide the deal team with a comprehensive overview of the principal tax issues arising from the transaction structure as currently contemplated, and to identify open items and action steps necessary to finalize the tax analysis prior to and following closing.
The transaction is structured as an asset purchase agreement ("APA") governed by Delaware law. Meridian will acquire substantially all assets, intellectual property, contracts, inventory, equipment, regulatory filings, and goodwill exclusively related to the OncuPath Business. GDT will retain all other business lines, including the GenoStrat™ liquid biopsy platform, and will continue as a going concern following the closing.
Total consideration for the transaction is $140,000,000, comprising a closing cash payment of $126,000,000 and up to $14,000,000 in clinical-milestone earnout payments contingent upon achievement of specified regulatory and reimbursement milestones within 36 months following closing. At closing, $14,000,000 will be deposited with Ashgrove Equity Partners Escrow Services, Inc. (Account No. 8841-7023-5500) to secure GDT's indemnification obligations under the APA.
This memorandum addresses the following key tax topics:
(1) The allocation of the purchase price among the acquired assets under IRC § 1060 and the residual method prescribed by the applicable Treasury Regulations;
(2) The character and timing of gain recognition by GDT at the corporate level, including depreciation and amortization recapture considerations;
(3) The apportionment of gain from the asset sale for California franchise tax purposes, given GDT's California headquarters and the California-situs nature of the OncuPath Business;
(4) The treatment of the earnout payments under the installment sale provisions of IRC § 453, including imputed interest considerations under IRC § 483;
(5) The impact of the transaction on distributions to Pinnacle Biosciences Partners Fund III, L.P. ("Pinnacle" or "PBP III"), GDT's 68.4% equity sponsor, including the double-tax consequences inherent in the C corporation structure; and
(6) IRS and state reporting requirements, including Form 8594 and Form 6252 filings.
Summary Conclusion. The asset purchase structure allows Buyer to receive a full step-up in tax basis across all acquired assets, which will enable Meridian to claim amortization and depreciation deductions with respect to the entire $140,000,000 purchase price over the applicable recovery periods. From the Seller's perspective, GDT will recognize gain at the corporate level on each category of transferred assets based on the difference between the allocated purchase price and the adjusted tax basis of the respective assets. The earnout payments, if and when received, may qualify for installment sale reporting under IRC § 453, which would provide a deferral benefit to GDT on the contingent $14,000,000 component of the purchase price. California franchise tax will apply to gain apportioned to or sourced in California, and will constitute a significant cost of the transaction given that the OncuPath Business is conducted entirely from California facilities.
The analysis set forth herein is preliminary and subject to revision upon receipt of final adjusted tax basis schedules from GDT's management and outside accountants, the final closing balance sheet and net working capital determination, and confirmation of certain factual assumptions identified throughout this memorandum.
II. Transaction Overview
A. Parties. Seller. Genome Dx Therapeutics Inc. is a Delaware corporation headquartered at 10250 Science Center Drive, Suite 600, San Diego, California 92121 (EIN 47-3892061). GDT is a C corporation for federal income tax purposes and files its federal income tax returns on a calendar-year basis. GDT operates in the precision diagnostics and genomic therapeutics markets, with its two principal business lines being the OncuPath™ companion diagnostics assay line and the GenoStrat™ liquid biopsy platform. For fiscal year 2022, GDT reported total consolidated revenue of approximately $312,000,000, of which the OncuPath Business contributed approximately $47,600,000, representing approximately 15.3% of GDT's consolidated revenue.
Buyer. Meridian Precision Diagnostics, Inc. is a Delaware corporation headquartered at 2400 Meridian Parkway, Suite 300, Durham, North Carolina 27713 (EIN 56-4210783). Meridian is a publicly traded precision diagnostics company specializing in oncology companion diagnostics. Meridian has identified the OncuPath Business as a strategic complement to its existing product portfolio and intends to integrate the acquired assay line into its North American commercial operations.
Equity Sponsor of Seller. Pinnacle Biosciences Partners Fund III, L.P. is a Delaware limited partnership (EIN 83-1726450) that holds approximately 68.4% of GDT's outstanding common stock. PBP III's general partner is Pinnacle Biosciences Partners GP III, LLC. The managing partners of the general partner are Nathaniel Hargrove and Priya Ramanathan. PBP III maintains its principal office at 600 Lexington Avenue, Suite 3100, New York, New York 10022. PBP III manages assets under management of approximately $4.2 billion across four funds. As the controlling equityholder of GDT, PBP III's economic interests and tax position are directly affected by the structure and tax treatment of the proposed transaction, and coordination with PBP III regarding distribution planning is essential, as discussed further in Section VII below.
The remaining approximately 31.6% of GDT's outstanding common stock is held by a combination of GDT founders, current and former management, and other minority investors. The identity and tax status of these minority holders may affect the character and timing of distributions from GDT but are not the primary focus of this memorandum.
B. Transaction Structure
The transaction is structured as an asset purchase — not a stock sale, merger, or other reorganization. This structure was selected after extensive negotiation between the parties and reflects the commercial and tax objectives of both Buyer and Seller.
Purchased Assets. Buyer will acquire all assets, intellectual property, contracts, inventory, equipment, regulatory filings, and goodwill exclusively related to the OncuPath™ companion diagnostics assay line. The Purchased Assets include, without limitation, the following:
• All patents, patent applications, trade secrets, know-how, and proprietary assay methodologies related to the OncuPath Business;
• All trademarks, service marks, and brand assets in the OncuPath brand family;
• All tangible personal property, including laboratory equipment, instruments, manufactured inventory, raw materials, and supplies used exclusively in the OncuPath Business;
• All contracts, customer agreements, hospital and reference laboratory network agreements, and supplier contracts exclusively related to the OncuPath Business;
• All regulatory filings, FDA submissions, clinical data packages, and quality system documentation related to the OncuPath assay products;
• All leasehold interests in the facilities at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121 and 925 Industrial Court, Carlsbad, California 92010;
• The exclusive license from Vantage Molecular Sciences, Inc. for probe-labeling technology pursuant to the License Agreement dated September 12, 2019; and
• All goodwill and going concern value attributable to the OncuPath Business.
Excluded Assets. The following assets are excluded from the transaction and will be retained by GDT:
• The GenoStrat™ liquid biopsy platform and all other retained GDT business lines;
• Corporate-level cash and cash equivalents;
• Tax refunds and credits attributable to pre-closing tax periods;
• GDT's corporate name, logos, and trademarks outside the OncuPath brand family;
• All assets not exclusively related to the OncuPath Business; and
• All employee benefit plan assets for non-transferred employees.
Assumed Liabilities. Buyer will assume only the following categories of liabilities:
• Post-closing trade payables arising under assumed contracts;
• Obligations under assumed contracts arising and accruing after the closing date;
• Product warranty claims for OncuPath assays shipped after the closing date; and
• Post-closing obligations under the assigned leases for the San Diego and Carlsbad facilities.
Excluded Liabilities. All pre-closing liabilities remain with GDT, including, without limitation:
• All liabilities and obligations arising prior to the closing date;
• Pending litigation matters involving GDT;
• Employee benefit plan obligations for non-transferred employees;
• Environmental liabilities at non-conveyed facilities; and
• Any tax liabilities of GDT arising from or in connection with the sale of the OncuPath Business.
C. Purchase Price Components
The total consideration for the transaction is $140,000,000, structured as follows:
Closing Cash Payment. At closing, Buyer will pay GDT $126,000,000 in cash by wire transfer of immediately available funds. This amount represents the total consideration of $140,000,000 less the maximum potential earnout of $14,000,000.
Earnout. In addition to the closing cash payment, Buyer will pay GDT up to $14,000,000 (representing 10% of total consideration) in contingent earnout payments upon the achievement of two clinical milestones within 36 months following the closing date, as follows:
Milestone 1 — $8,000,000. Payable upon FDA clearance or approval of the OncuPath-HER3™ assay as a companion diagnostic for any FDA-approved therapeutic agent, on or before August 8, 2025 (24 months post-closing). This milestone is tied to the regulatory pathway currently being pursued by GDT's clinical and regulatory affairs team for the OncuPath-HER3™ assay, which is designed to identify patients eligible for HER3-targeted therapies. If the milestone is not achieved by the specified deadline, no payment is owed and the obligation terminates.
Milestone 2 — $6,000,000. Payable upon (a) the Centers for Medicare & Medicaid Services ("CMS") issuance of a unique Healthcare Common Procedure Coding System ("HCPCS") code for the OncuPath-HER3™ assay (or its successor assay), and (b) receipt by Buyer of the first Medicare reimbursement payment under such code, in each case on or before August 8, 2026 (36 months post-closing). This milestone reflects the commercial viability of the assay in the Medicare reimbursement environment and is expected to be achievable if Milestone 1 is met within the specified timeframe.
The earnout milestones are structured as binary, all-or-nothing payments — partial achievement of a milestone does not result in any partial payment. Each milestone is independently determinable, meaning that achievement of Milestone 2 is not conditioned on prior achievement of Milestone 1 (although, as a practical matter, FDA clearance or approval would ordinarily precede CMS coding and reimbursement).
Escrow. At closing, $14,000,000 will be deposited with Ashgrove Equity Partners Escrow Services, Inc. (Account No. 8841-7023-5500) to secure GDT's indemnification obligations under Article IX of the APA. The escrow amount is funded from the closing cash payment and does not represent contingent consideration. The release schedule for the escrow is as follows:
• First Release (August 8, 2024): 50% of the then-remaining escrow balance will be released to GDT on the first anniversary of the closing date, net of any pending indemnification claims.
• Final Release (February 8, 2025): The entire remaining escrow balance will be released to GDT upon expiration of the 18-month indemnification survival period, net of any pending or unresolved indemnification claims.
The tax treatment of the escrow is discussed in Section V.D below.
D. Key Dates
The following timetable sets forth the key dates relevant to the transaction and the related tax analysis:
The actual closing date of August 8, 2023 establishes the date on which the asset sale is consummated for federal and state income tax purposes. Gain recognition, basis determination, and allocation calculations are all keyed to this date.
III. Federal Income Tax Analysis — Seller's Gain Recognition
A. Asset Sale Treatment
GDT is organized as a C corporation under the laws of the State of Delaware and is taxable as a C corporation for federal income tax purposes under Subchapter C of the Internal Revenue Code. The proposed transaction is structured as a sale of individual assets constituting the OncuPath Business — it is not a sale of stock, a statutory merger, or any other form of corporate reorganization.
Because the transaction is an asset sale, GDT will recognize gain or loss on each asset sold based on the difference between the "amount realized" (i.e., the portion of the purchase price allocated to that asset under IRC § 1060) and GDT's adjusted tax basis in the respective asset at the time of closing. This is the fundamental operative principle governing the Seller-side tax consequences of the transaction.
It is important to note certain structural alternatives that are not applicable here. Unlike a stock sale followed by a Section 338(h)(10) election — in which the target would be treated as having sold all of its assets in a deemed asset sale, but the buyer would acquire stock and the transaction would be taxed only at the corporate level — the present transaction involves an actual transfer of assets from GDT to Meridian. Accordingly, no Section 338 election is available or necessary, as the transaction is already an asset sale by its terms.
Similarly, no Section 338(h)(10) election is available because no stock is being acquired. That election is available only when a purchasing corporation acquires the stock of a target S corporation or target that is a member of an affiliated group filing a consolidated return. The asset purchase structure here renders that election entirely inapplicable.
GDT will be the recognizing taxpayer for all gain arising from the sale of the Purchased Assets. Gain will be computed and reported on GDT's federal income tax return for the taxable year ending December 31, 2023 (the taxable year in which the closing occurs). The character of gain — ordinary income versus capital gain — will vary by asset class, as discussed below.
B. Character of Gain
The character of gain recognized by GDT on the sale of the OncuPath Business assets will depend on the nature of each asset and the applicable provisions of the Internal Revenue Code governing the sale of that asset class. The following analysis addresses each major category of Purchased Assets:
Tangible Personal Property (Equipment, Inventory, and Supplies). Gain on the sale of tangible personal property — including laboratory equipment, instruments, manufactured inventory, raw materials, and supplies — will be characterized as follows:
• Equipment: To the extent GDT has claimed depreciation deductions with respect to equipment used in the OncuPath Business, gain on the sale of such equipment will be treated as ordinary income to the extent of depreciation recapture under IRC § 1245. Under § 1245(a)(1), gain on the disposition of "section 1245 property" is treated as ordinary income to the extent of the lesser of (a) the gain realized or (b) the depreciation previously allowed or allowable. Any gain in excess of the depreciation recapture amount will be treated as Section 1231 gain, which, if net Section 1231 gains exceed net Section 1231 losses for the taxable year, will be long-term capital gain (subject to the Section 1231(c) lookback rule for net Section 1231 losses in the preceding five taxable years).
• Inventory: Gain on the sale of inventory is ordinary income in all cases. IRC § 1221(a)(1) excludes inventory and property held primarily for sale to customers in the ordinary course of business from the definition of "capital asset." Accordingly, no portion of the gain allocated to inventory will qualify for capital gain treatment.
Real Property Interests (Leasehold Interests). GDT holds leasehold interests in two facilities used in the OncuPath Business: the primary laboratory and office space at 4820 Towne Centre Drive, Suite 200, San Diego, California 92121 and the secondary manufacturing and storage facility at 925 Industrial Court, Carlsbad, California 92010. Gain on the assignment or sale of these leasehold interests will be subject to analysis under IRC § 1250, which governs depreciation recapture on the disposition of "section 1250 property" (depreciable real property).
Under § 1250, depreciation recapture on real property is limited to the excess of accelerated depreciation over straight-line depreciation. For leasehold improvements placed in service after 1986, the applicable depreciation method is generally the straight-line method, meaning that § 1250 recapture is typically minimal or zero. In such cases, the gain would be characterized as Section 1231 gain, which — if net Section 1231 gains exceed net Section 1231 losses — would be treated as long-term capital gain. The actual depreciation history of GDT's leasehold improvements must be confirmed with the GDT finance team and Haverford & Lane LLP.
intellectual Property (Patents, Trade Secrets, Know-How). The intellectual property assets being transferred include 14 issued U.S. patents, 7 pending patent applications, trade secrets, proprietary know-how, and the exclusive license from Vantage Molecular Sciences, Inc.
• Patents: Under IRC § 1235, the transfer of "all substantial rights" to a patent by a "holder" (including the creator of the patent or a person who acquired the patent from the creator before the invention was "reduced to practice") is treated as a sale or exchange of a long-term capital asset, regardless of how long the patent was held. For self-created patents, § 1235 provides long-term capital gain treatment even though self-created patents would otherwise be excluded from the definition of "capital asset" under § 1221(a)(3) (copyrights and artistic compositions). However, for patents that were acquired by GDT through a prior acquisition (as may be the case for portions of the OncuPath patent portfolio acquired in legacy transactions), the character of gain will depend on whether the patents constitute Section 1231 property or capital assets in GDT's hands. In either case, long-term capital gain treatment is generally available for patents held for more than one year.
• Trade Secrets and Know-How: Trade secrets and unpatented know-how do not qualify for the preferential treatment afforded to patents under § 1235. To the extent trade secrets constitute self-created intellectual property, they may be excluded from the definition of "capital asset" under § 1221(a)(3). Gain on the sale of self-created trade secrets would therefore be ordinary income. However, if the trade secrets were acquired by GDT in a prior acquisition and are treated as amortizable Section 197 intangibles, recapture rules may apply, as discussed below.
Customer Relationships and Contracts. Customer relationships, customer lists, and assumed commercial contracts are generally treated as amortizable Section 197 intangibles with a 15-year amortization period. To the extent GDT has an adjusted tax basis in these intangibles (e.g., if they were acquired in a prior acquisition and have been partially amortized), gain on the sale will be ordinary income to the extent of amortization recapture under IRC § 197(f)(7) (which cross-references the recapture rules of § 1245). Any gain in excess of the recapture amount will be capital gain.
Trademarks and Trade Names. The OncuPath™, OncuPath-HER3™, and OncuPath-GENOMARK™ trademarks are registered with the United States Patent and Trademark Office and constitute Section 197 intangibles. As with customer relationships, gain on the sale of these trademarks will be ordinary income to the extent of amortization recapture under § 197(f)(7), and capital gain on the excess.
Goodwill. Goodwill and going concern value are Section 197 intangibles. To the extent GDT has an adjusted tax basis in goodwill (which would be the case if goodwill was acquired in a prior acquisition and has been partially amortized), gain on the sale will be ordinary income to the extent of amortization recapture and capital gain on the excess. To the extent goodwill is self-created and GDT has zero or minimal basis, substantially all of the gain allocated to goodwill will be capital gain, as the amount realized will exceed the adjusted basis by the full allocated amount.
C. Estimated Aggregate Gain
A precise calculation of GDT's aggregate gain on the sale of the OncuPath Business assets cannot be completed at this time because we have not yet received final adjusted tax basis schedules for all transferred assets. We have requested these schedules from Martin Kowalski, GDT's Chief Financial Officer, and from Douglas Crane, the engagement partner at Haverford & Lane LLP, GDT's outside accounting firm. We expect to receive preliminary basis information within two to three weeks and final schedules following the closing balance sheet preparation.
Notwithstanding the foregoing, our preliminary assessment is that GDT will recognize substantial gain across all asset classes. This expectation is based on the following factors:
• A significant portion of the OncuPath intellectual property and goodwill is self-created, meaning GDT has zero or minimal tax basis in these assets. The $52,600,000 preliminary allocation to intellectual property and $28,600,000 allocation to goodwill will generate substantial gain.
• Assets acquired by GDT in legacy transactions have been subject to ongoing amortization and depreciation, reducing their adjusted tax basis over time.
• The $140,000,000 purchase price represents a significant premium over GDT's aggregate historical cost basis in the OncuPath Business assets.
For context, GDT's total consolidated revenue for fiscal year 2022 was approximately $312,000,000. The OncuPath Business contributed approximately $47,600,000 of that total, representing approximately 15.3% of GDT's consolidated revenue. However, the gain on the sale of the OncuPath Business will be recognized entirely at the GDT corporate level, with the full amount subject to federal and state income taxation.
D. Corporate-Level Tax Rate
GDT's gain on the asset sale will be subject to the federal corporate income tax at a rate of 21% under IRC § 11, as amended by the Tax Cuts and Jobs Act of 2017. This rate applies uniformly to all taxable income of C corporations, regardless of whether the income is characterized as ordinary income or capital gain (C corporations do not benefit from preferential capital gains rates).
The net investment income tax under IRC § 1411 does not apply to C corporations; it is imposed only on individuals, estates, and trusts with net investment income exceeding certain thresholds.
GDT's estimated federal income tax liability on the gain from the asset sale will be calculated once final basis schedules are received and the gain by asset class is determined. As a preliminary matter, if the aggregate gain were equal to the full $140,000,000 purchase price (a worst-case scenario assuming zero basis), the federal tax would be approximately $29,400,000. The actual gain — and therefore the actual tax — will be lower to the extent GDT has adjusted tax basis in the transferred assets.
In addition to federal income tax, GDT will be subject to California franchise tax on the gain apportioned to California, as discussed in Section VI below.
IV. Purchase Price Allocation Under IRC § 1060
A. Legal Framework
IRC § 1060 governs the allocation of consideration in an "applicable asset acquisition" — defined as any transfer of assets constituting a trade or business in which the transferee's basis in the transferred assets is determined wholly by reference to the consideration paid for the assets. The proposed acquisition of the OncuPath Business by Meridian qualifies as an applicable asset acquisition within the meaning of § 1060, because (i) Meridian is acquiring a group of assets that constitutes a trade or business, and (ii) Meridian's basis in the acquired assets will be determined by reference to the purchase price paid.
Under § 1060, both the buyer and the seller are required to allocate the total consideration paid for the acquired assets among those assets using the "residual method" prescribed by IRC § 338(b)(5) and the related Treasury Regulations §§ 1.338-6 and 1.338-7. The residual method requires the total consideration to be allocated first to assets in the lowest asset classes (beginning with cash and cash equivalents) up to their fair market values, with any remaining unallocated consideration assigned to the highest asset class — goodwill and going concern value — as a residual.
Both parties to an applicable asset acquisition are required to file IRS Form 8594 (Asset Acquisition Statement Under Section 1060) with their respective federal income tax returns for the taxable year in which the acquisition occurs. The allocation reported on each party's Form 8594 must be consistent; if the parties agree on the allocation, both should report the same figures. If the parties cannot agree, each files its own Form 8594 reflecting its own allocation, but inconsistent filings increase the risk of IRS examination and controversy.
Article II, Section 2.5 of the APA requires the Seller and Buyer to agree upon a purchase price allocation within 120 days following the closing date, which, based on an August 8, 2023 closing, establishes a deadline of December 6, 2023. The APA further provides that, if the parties agree on the allocation, both parties shall report the transaction on their respective tax returns in a manner consistent with the agreed-upon allocation and shall not take any position inconsistent therewith in any tax proceeding, audit, or examination. This binding allocation provision is a critical element of the transaction structure, as it minimizes the risk of inconsistent reporting and potential IRS challenge.
We strongly recommend that the deal team engage promptly with Buyer's counsel — Whitfield Sayer & Gregg LLP (Jonathan Whitfield and Rachel Dempsey) — to negotiate and finalize the allocation well before the December 6, 2023 contractual deadline. The preliminary allocation set forth in Section IV.C below should serve as our starting point for negotiations.
B. Asset Classes Under the Residual Method
Treasury Regulation § 1.338-6(b) prescribes seven asset classes for purposes of the residual method. The total consideration is allocated sequentially to each class in order, beginning with Class I and ending with Class VII. The allocation to each class is limited to the aggregate fair market value of the assets within that class, with any remaining unallocated consideration flowing down to the next class. The following is a summary of the seven classes and their application to the OncuPath Business acquisition:
Class I — Cash and Cash Equivalents. Allocation: $0. Corporate-level cash and cash equivalents are excluded from the Purchased Assets under the APA. No Class I allocation is required.
Class II — Actively Traded Personal Property, Certificates of Deposit, and Foreign Currency. Allocation: $0. The OncuPath Business does not include any actively traded personal property, certificates of deposit, U.S. government securities, or foreign currency. No Class II allocation is required.
Class III — Accounts Receivable, Mortgages, and Credit Card Receivables (Mark-to-Market Assets). The Purchased Assets include accounts receivable and other working capital items related to the OncuPath Business. These items are included in the net working capital adjustment mechanism described in Section IV.E below. The allocation to Class III will be determined based on the final closing net working capital. For purposes of the preliminary allocation set forth in Section IV.C, we have assumed that closing net working capital equals the target of $6,800,000, and the Class III component is subsumed within the tangible personal property and working capital line items.
Class IV — Inventory and Stock in Trade. The Purchased Assets include manufactured OncuPath assay kits, raw materials, and work-in-process inventory. These items are included in the tangible personal property allocation. Inventory is allocated at fair market value, which for manufactured goods is typically the selling price less costs to sell.
Class V — All Assets Not in Classes I–IV, VI, or VII. This class includes tangible personal property other than inventory (e.g., laboratory equipment, instruments, furniture and fixtures), as well as real property interests (leasehold interests in the San Diego and Carlsbad facilities). The combined preliminary allocation to Classes IV and V is $21,600,000, comprising $18,200,000 for tangible personal property (equipment, inventory, and supplies) and $3,400,000 for real property interests (leasehold interests).
Class VI — Section 197 Intangibles Other Than Goodwill and Going Concern Value. This class includes patents, patent applications, trade secrets, know-how, customer relationships, contracts, trademarks, trade names, and other intangible assets that qualify as Section 197 intangibles. The combined preliminary allocation to Class VI is $89,800,000, comprising $52,600,000 for intellectual property, $27,800,000 for customer relationships and contracts, and $9,400,000 for trademarks and trade names.
Class VII — Goodwill and Going Concern Value (Residual). The residual after allocating consideration to Classes I through VI is assigned to goodwill and going concern value. The preliminary residual allocation to Class VII is $28,600,000.
C. Preliminary Purchase Price Allocation
Based on our preliminary analysis of the fair market values of the Purchased Assets, discussions with GDT management, and review of available valuation data, we propose the following preliminary purchase price allocation:
The goodwill residual is calculated as follows:
$140,000,000 − ($18,200,000 + $3,400,000 + $52,600,000 + $27,800,000 + $9,400,000) = $28,600,000
This preliminary allocation assumes that closing net working capital equals the target of $6,800,000 and that the total consideration is $140,000,000 (assuming all earnout milestones are achieved). Adjustments to the total consideration — whether due to the NWC true-up or the non-achievement of earnout milestones — will require a corresponding revision to the allocation, with the adjustment flowing primarily to the goodwill residual.
D. Allocation Considerations and Sensitivities
The following considerations inform the preliminary allocation and will be relevant to the negotiation of the final allocation with Buyer's counsel:
intellectual Property Allocation ($52,600,000). The intellectual property allocation is the single largest component of the purchase price, reflecting the central importance of the OncuPath patent portfolio and proprietary assay technology to the value of the OncuPath Business. The IP allocation is supported by the following factors:
• GDT holds 14 issued U.S. patents and 7 pending patent applications covering the OncuPath assay platform, including claims directed to assay compositions, methods of detection, and probe-labeling technologies;
• GDT holds an exclusive license from Vantage Molecular Sciences, Inc. pursuant to the License Agreement dated September 12, 2019, which grants GDT exclusive rights to certain probe-labeling technology integral to the OncuPath assay methodology;
• The portfolio includes proprietary know-how and trade secrets relating to assay design, manufacturing processes, and quality control protocols that are not disclosed in the patent filings; and
• An independent valuation report may be warranted to support the IP allocation, particularly given its magnitude relative to the total purchase price (37.6% of total consideration).
Customer Relationships Allocation ($27,800,000). The customer relationships allocation reflects the established hospital system and reference laboratory customer base of the OncuPath Business. GDT's OncuPath Business generated $47,600,000 in revenue in fiscal year 2022 from contracts with major hospital systems, academic medical centers, and commercial reference laboratories. The customer relationships have demonstrated longevity and low churn rates, supporting a significant allocation.
Trademarks Allocation ($9,400,000). The trademark allocation reflects three registered marks — OncuPath™ (Reg. No. 5,847,321), OncuPath-HER3™ (Reg. No. 6,412,088), and OncuPath-GENOMARK™ (Reg. No. 6,118,754) — with demonstrated brand recognition in the companion diagnostics market. The trademarks are integral to the commercial identity of the OncuPath product line and carry value independent of the underlying technology.
Goodwill Residual ($28,600,000). The goodwill residual represents the going concern value of the OncuPath Business, including the value of the assembled workforce (of the 83 OncuPath employees offered employment by Meridian, 78 have accepted), established market position, customer goodwill, and other intangible value not captured by the specific asset categories above.
Buyer's vs. Seller's Interests. As a general matter, the Buyer's tax interest is to allocate as much consideration as possible to short-lived assets (e.g., tangible personal property with 5-year or 7-year MACRS recovery periods, or customer relationships with shorter estimated useful lives) in order to accelerate tax deductions. The Seller's interest at the corporate level is more nuanced: because C corporations are taxed at a flat 21% rate on both ordinary income and capital gains, the rate differential does not apply at the GDT corporate level. However, the character of gain may affect the character of distributions to shareholders (including PBP III) and may have implications for PBP III's limited partners. In general, the Seller prefers capital gain characterization where possible.
Recommendation. We recommend that the deal team present the preliminary allocation set forth above to Whitfield Sayer & Gregg LLP as a reasonable starting point for negotiations. The allocation is defensible based on available information and industry benchmarks for companion diagnostics businesses. An independent valuation study (e.g., by a Big Four accounting firm or a specialized valuation firm) may be advisable to support the allocation if the IRS challenges the Form 8594 filing.
E. Working Capital Adjustment Impact on Allocation
The APA includes a customary net working capital adjustment mechanism. The target net working capital ("Target NWC") is $6,800,000, with a collar of ±$350,000. The true-up process operates as follows:
• Within 90 days following the closing date (deadline: November 6, 2023), the final closing balance sheet will be prepared by Haverford & Lane LLP, and the actual closing NWC will be determined.
• If the actual closing NWC exceeds the Target NWC by more than $350,000 (i.e., exceeds $7,150,000), Buyer will pay the excess over $7,150,000 to Seller as a purchase price adjustment.
• If the actual closing NWC is less than the Target NWC by more than $350,000 (i.e., is below $6,450,000), Seller will pay the shortfall below $6,450,000 to Buyer as a purchase price adjustment.
• Adjustments within the collar (i.e., actual NWC between $6,450,000 and $7,150,000) do not result in any payment.
Any NWC adjustment will affect the total purchase price and therefore the total allocation. If the total consideration is increased by an NWC adjustment, the additional consideration will be allocated among the asset classes pursuant to the residual method, with the adjustment flowing primarily to Class III (receivables) or Class IV (inventory) to the extent the adjustment relates to changes in those specific working capital components, and any remainder to the goodwill residual. If the total consideration is decreased, the reduction would similarly be reflected in the allocation, with the primary adjustment flowing to the goodwill residual.
The preliminary allocation set forth in Section IV.C above assumes that the actual closing NWC equals the Target NWC of $6,800,000 and that no NWC adjustment payment is made.
V. Earnout Payments — Installment Sale Analysis
A. IRC § 453 Installment Method
The earnout component of the purchase price — up to $14,000,000 in clinical-milestone payments — constitutes "contingent consideration" for purposes of the installment sale provisions of IRC § 453. Milestone 1 ($8,000,000) is contingent on FDA clearance or approval of the OncuPath-HER3™ assay by August 8, 2025, and Milestone 2 ($6,000,000) is contingent on CMS issuance of a unique HCPCS code and receipt of first Medicare reimbursement by August 8, 2026. Neither milestone payment is guaranteed, and neither will be paid unless the applicable clinical and regulatory conditions are satisfied.
Under IRC § 453 and the regulations thereunder — specifically Treasury Regulations § 15a.453-1(c) — a sale of property for contingent payments may be reported under the installment method, provided that the transaction does not involve the sale of inventory or dealer dispositions and the taxpayer does not elect out of installment sale treatment. The installment method allows the taxpayer to defer recognition of gain on contingent payments until the payments are actually received.
Treasury Regulations § 15a.453-1(c) provides three sets of rules for contingent payment sales, depending on whether: (1) a maximum selling price is determinable, (2) a fixed payment period is established, or (3) neither condition is met.
In this transaction, the maximum selling price is determinable. The total consideration — including both the closing cash payment and the maximum earnout — is $140,000,000. Accordingly, the rules for contingent payment sales with a stated maximum selling price apply.
Under these rules, the seller's basis in the transferred assets is recovered ratably over the maximum selling price. Specifically, GDT's total adjusted tax basis in the transferred OncuPath Business assets will be allocated across the total $140,000,000 of potential consideration, and a proportionate share of basis will be recovered against each payment received. The "gross profit ratio" (i.e., the ratio of total gain to total contract price) will be applied to each payment to determine the gain recognized upon receipt.
Each earnout payment, if and when received, will be allocated among the asset classes in the same proportion as the closing allocation under § 1060. Gain will be recognized on each earnout payment as received, and the character of the gain — ordinary income or capital gain — will correspond to the character of the underlying asset classes to which the earnout payment is allocated.
If a milestone is not achieved and the corresponding earnout payment is never made, the unreceived payment will reduce the total consideration and the allocation will be adjusted accordingly. GDT may need to file an amended Form 8594 to reflect the revised total consideration.
B. Alternative Treatment — Open Transaction
Under the "open transaction" doctrine established by the Supreme Court in Burnet v. Logan, 283 U.S. 404 (1931), a sale for contingent consideration where the fair market value of the contingent payment right cannot be reasonably determined may be treated as an "open transaction," with the seller deferring gain recognition until basis is fully recovered. Under this approach, all payments are treated first as a return of basis, with gain recognized only after the seller's entire basis has been recovered.
The open transaction doctrine is narrowly applied and is generally available only when the contingent payment right is truly incapable of valuation. The IRS has historically been hostile to open transaction treatment, and the Tax Court has limited its application to exceptional circumstances.
In this transaction, the open transaction doctrine is likely inapplicable because the maximum earnout is capped at $14,000,000, meaning the maximum selling price is determinable. The existence of a stated maximum selling price brings the transaction squarely within the contingent payment installment sale rules of Treasury Regulations § 15a.453-1(c)(2), and removes any basis for invoking the open transaction doctrine.
Recommendation. We recommend that GDT report the earnout component of the purchase price under the installment method with a stated maximum selling price of $140,000,000. This approach provides a deferral benefit on the contingent $14,000,000 while complying with the applicable Treasury Regulations.
C. IRC § 483 / § 1274 — Imputed Interest
The earnout payments, if received, will be deferred beyond one year from the closing date. Milestone 1 is payable on or before August 8, 2025 (24 months post-closing), and Milestone 2 is payable on or before August 8, 2026 (36 months post-closing). Deferred payments in a sale of property may give rise to imputed interest under the original issue discount ("OID") provisions of IRC § 1274 or, alternatively, under the unstated interest provisions of IRC § 483.
Section 1274 applies to "debt instruments" issued in exchange for property, requiring the instrument to carry adequate stated interest. If the stated interest is less than the applicable federal rate ("AFR"), interest is imputed at the AFR. However, § 1274 generally applies to fixed obligations — i.e., debt instruments with a stated principal amount and fixed payment schedule. Contingent earnout payments that are not evidenced by a fixed debt instrument typically fall outside the scope of § 1274.
Section 483, by contrast, applies to "payments on account of the sale or exchange of property" where some or all of the payments are due more than one year after the sale, and where the total payments do not carry adequate stated interest. Section 483 operates to recharacterize a portion of each deferred payment as "unstated interest," which is treated as ordinary interest income to the seller (and as deductible interest expense to the buyer) rather than as consideration for the property sold.
Because the earnout payments are contingent and are not evidenced by a fixed debt instrument, § 483 — rather than § 1274 — is the operative provision. A portion of each earnout payment may therefore be recharacterized as imputed interest income (ordinary income) to GDT, reducing the amount treated as consideration for the OncuPath Business assets.
The imputed interest rate is determined by reference to the AFR in effect at the time of closing. The AFR is published monthly by the IRS for short-term (not over three years), mid-term (over three years but not over nine years), and long-term (over nine years) instruments. Given that the earnout payments are due within 36 months of closing, the short-term or mid-term AFR will likely apply.
Recommendation. We recommend monitoring the AFR as of August 2023 (the closing month) and calculating the imputed interest component for each milestone payment. The imputed interest calculation will affect both the amount of gain recognized on each earnout payment and the character of income (ordinary interest income versus sale gain). We will provide a supplemental analysis on imputed interest once the closing AFR is known.
D. Escrow Treatment
The $14,000,000 escrow deposit must be distinguished from the earnout for tax purposes. The escrow is not contingent consideration — it represents a portion of the $126,000,000 closing cash payment that is withheld at closing and deposited with Ashgrove Equity Partners Escrow Services, Inc. to secure GDT's indemnification obligations under the APA. The full $14,000,000 escrow is funded at closing from the closing cash payment.
Under established tax principles — specifically Rev. Rul. 77-294 and the economic benefit doctrine — the escrow amount is included in GDT's amount realized in the year of closing (2023), regardless of when the escrowed funds are actually released to GDT. The rationale is that the escrow represents consideration that has been unconditionally paid by the buyer; the fact that it is held by an independent escrow agent pending resolution of potential indemnification claims does not defer the seller's recognition of the amount.
Accordingly, GDT will include the full $14,000,000 escrow in its amount realized for the 2023 tax year, along with the $112,000,000 paid directly to GDT at closing (i.e., $126,000,000 less $14,000,000 escrow = $112,000,000 paid directly, plus $14,000,000 in escrow = $126,000,000 total closing cash payment). The escrow is reported as part of the closing consideration and allocated among asset classes under the § 1060 allocation.
Interest or investment income earned on the escrowed funds will be allocated and taxed pursuant to the terms of the Escrow Agreement. Typically, interest income is taxable to the party entitled to the income as it accrues or is earned. The Escrow Agreement should specify the allocation of interest between the parties; if interest is allocated to GDT, it will be reported as ordinary income by GDT in the year earned.
The first release of escrow funds (50% of the remaining balance at August 8, 2024) and the final release (balance at February 8, 2025) are releases of previously recognized amounts, not additional income events. No additional gain or loss is recognized by GDT upon release of the escrow, except to the extent that indemnification claims reduce the escrow balance — in which case GDT may recognize a loss or reduction in amount realized, potentially requiring adjustment to the original gain computation and the § 1060 allocation.
VI. California State Tax Implications
A. California Franchise Tax — Corporate Level
GDT is headquartered in San Diego, California and conducts the entirety of the OncuPath Business from California facilities — the primary laboratory and office space at 4820 Towne Centre Drive, Suite 200, San Diego, and the secondary manufacturing and storage facility at 925 Industrial Court, Carlsbad. GDT is subject to the California franchise tax as a corporation doing business in California.
California imposes the franchise tax on C corporations at a rate of 8.84% on net income apportioned to California, pursuant to California Revenue and Taxation Code ("R&TC") § 23151. This tax is in addition to the federal corporate income tax of 21%, resulting in a combined federal and California effective tax rate of approximately 29.84% on income apportioned to California (before considering the federal deduction for state taxes, which is not available under current law for C corporations following the Tax Cuts and Jobs Act's elimination of the corporate alternative minimum tax and the inapplicability of the SALT cap to corporations).
Gain recognized by GDT on the sale of the OncuPath Business assets will be included in GDT's California taxable income for the 2023 taxable year, subject to apportionment as discussed below.
B. Apportionment of Sale Gain
California has adopted a single-factor sales apportionment formula for most taxpayers, effective for taxable years beginning on or after January 1, 2013, pursuant to R&TC § 25128.7. Under this formula, a taxpayer's California-source income is determined by multiplying the taxpayer's total business income by a fraction, the numerator of which is the taxpayer's California sales and the denominator of which is the taxpayer's total sales everywhere.
The application of the single-factor sales apportionment formula to gain from the sale of business assets depends on the nature of the assets sold:
Gain from the Sale of Intangible Assets (IP, Goodwill, Customer Relationships, Trademarks). Gain from the sale of intangible assets used in a trade or business is generally classified as "business income" under California's Uniform Division of Income for Tax Purposes Act ("UDITPA") and is apportioned using the taxpayer's overall California apportionment factor. The California Franchise Tax Board ("FTB") has taken the position that gain from the sale of intangible assets that are part of the taxpayer's unitary business is apportionable business income, rather than allocable nonbusiness income.
Because the OncuPath Business is conducted entirely in California, GDT's California apportionment factor is likely to be significant. However, the apportionment factor is determined by reference to GDT's total business operations, not just the OncuPath Business. If GDT has substantial sales outside California through its GenoStrat™ business or other retained operations, the California apportionment factor may be lower than 100%, resulting in less than all of the gain being apportioned to California.
Gain from the Sale of Tangible Personal Property. Under R&TC § 25135, gains from the sale of tangible personal property are generally sourced to the state where the property is located at the time of sale. The OncuPath equipment, inventory, and supplies are located at the San Diego and Carlsbad facilities, which are both in California. Accordingly, gain from the sale of tangible personal property will be sourced to California.
Gain from Real Property Interests (Leasehold Interests). Gain from the sale or assignment of real property interests is sourced to the state where the real property is located. The leasehold interests at 4820 Towne Centre Drive, San Diego and 925 Industrial Court, Carlsbad are California-situs property. Gain from the transfer of these leasehold interests will be sourced entirely to California.
Estimated Impact. We expect that a substantial portion of GDT's gain on the sale of the OncuPath Business will be apportioned to or sourced in California, given the California-situs nature of the OncuPath Business assets and operations. The precise California franchise tax liability cannot be quantified until the final gain calculations are completed. However, at an 8.84% rate, the California franchise tax will represent a significant cost of the transaction. For illustrative purposes, if 60% of the total gain were apportioned to California, and the total gain were approximately $120,000,000 (a rough estimate pending final basis determination), the California franchise tax would be approximately $6,365,000. This estimate is preliminary and will be revised once final basis schedules and the California apportionment factor are determined.
C. California Withholding
No California withholding on the sale proceeds is required because GDT is a California taxpayer — i.e., GDT is incorporated in Delaware but is headquartered and doing business in California, files California franchise tax returns, and is not a nonresident or foreign entity for California tax purposes.
If GDT were a nonresident or foreign entity, California R&TC § 18662 would require the buyer to withhold 7% of the gross sales price attributable to California-source income and remit the withheld amount to the FTB. This provision is not applicable here, but the deal team should confirm that no similar withholding obligations arise under the laws of any other state in which GDT conducts business.
D. Other State Considerations
North Carolina. Meridian is headquartered in Durham, North Carolina. The fact that the Buyer is a North Carolina entity does not give rise to any North Carolina income tax liability for GDT as the Seller. North Carolina does not impose income tax on a nonresident seller merely because the buyer is a North Carolina resident. Unless GDT has independent nexus with North Carolina — e.g., through sales of OncuPath products to North Carolina customers — North Carolina should not impose income tax on GDT's gain from the asset sale. We recommend confirming whether GDT has any North Carolina nexus.
Delaware. GDT is incorporated in Delaware but does not conduct business operations in Delaware. Delaware does not impose a corporate income tax on entities that are merely incorporated in the state but do not conduct business activities within the state. Accordingly, no Delaware corporate income tax consequence is expected to result from the asset sale.
Multistate Nexus. We recommend confirming whether GDT has nexus in any other states through OncuPath Business operations — for example, through the sale of OncuPath assay products to customers in states that impose economic nexus thresholds. If GDT has nexus in additional states, multistate apportionment may apply, and GDT may be subject to income tax in those states on a portion of the gain from the asset sale. We are not aware of any significant nexus concerns at this time, but this should be verified with GDT's finance team and Haverford & Lane LLP.
VII. Impact on Pinnacle Biosciences Partners Fund III, L.P. Distributions
A. Corporate-Level Tax First
Because GDT is a C corporation, gain on the sale of the OncuPath Business assets is recognized and taxed first at the GDT corporate level. GDT will pay federal corporate income tax at 21% and California franchise tax at 8.84% (on the portion of gain apportioned to California) on its gain from the sale. The net after-tax proceeds — i.e., the sale proceeds less GDT's corporate income tax liability — will be available for distribution to GDT's shareholders.
This corporate-level tax is a first layer of taxation. Any subsequent distribution of the net after-tax proceeds to GDT's shareholders will give rise to a second layer of tax at the shareholder level, as discussed below.
B. Distribution to PBP III
Pinnacle Biosciences Partners Fund III, L.P. holds approximately 68.4% of GDT's outstanding common stock and is the controlling equityholder. Distribution of sale proceeds from GDT to PBP III will be treated for federal income tax purposes based on the following ordering rules under IRC § 301:
(1) Dividend. To the extent of GDT's current and accumulated earnings and profits ("E&P"), distributions to PBP III will be treated as dividends. Qualified dividends received by non-corporate shareholders (including individual limited partners of PBP III) are taxed at preferential long-term capital gains rates (currently 0%, 15%, or 20%, depending on the recipient's taxable income). Dividends received by corporate shareholders may qualify for the dividends-received deduction under IRC § 243.
(2) Return of Capital. To the extent distributions exceed GDT's E&P, they are treated as a tax-free return of capital, reducing the shareholder's adjusted basis in its GDT stock.
(3) Capital Gain. To the extent distributions exceed both E&P and the shareholder's adjusted basis in its GDT stock, the excess is treated as gain from the sale or exchange of the stock — typically long-term capital gain if the stock has been held for more than one year.
An E&P analysis will be necessary to determine the character of distributions from GDT to PBP III and the other shareholders. This analysis should be coordinated with GDT's finance team and Haverford & Lane LLP.